{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:47:32Z","timestamp":1786988852985,"version":"build-2736575974"},"reference-count":98,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.esmoop.2023.102050","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T16:12:45Z","timestamp":1697127165000},"page":"102050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice"],"prefix":"10.1016","volume":"8","author":[{"given":"P.","family":"Grivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0134-4732","authenticated-orcid":false,"given":"E.","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-8244","authenticated-orcid":false,"given":"I.D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.H.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-O.","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3868-186X","authenticated-orcid":false,"given":"P.","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2023.102050_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102050_bib2","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.esmoop.2023.102050_bib3","first-page":"1383","article-title":"Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer","volume":"21","author":"Singer","year":"2013","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102050_bib4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bju.14047","article-title":"Impact of bladder cancer on health-related quality of life","volume":"121","author":"Smith","year":"2018","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.esmoop.2023.102050_bib5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","article-title":"The health economics of bladder cancer: an updated review of the published literature","volume":"32","author":"Yeung","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.esmoop.2023.102050_bib8","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: an update","volume":"38","author":"Richters","year":"2020","journal-title":"World J Urol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102050_bib9","article-title":"A\u00a0review of the etiology and epidemiology of bladder cancer: all you need to know","volume":"14","author":"Halaseh","year":"2022","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102050_bib10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2023.102050_bib11","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/cam4.2958","article-title":"Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease","volume":"9","author":"Taarnh\u00f8j","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102050_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2021","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.esmoop.2023.102050_bib14","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2023.102050_bib15","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2023.102050_bib16","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \"unfit\" for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102050_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/annonc\/mdx692","article-title":"Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive\/Advanced Cancer of the Urothelium (RISC)","volume":"29","author":"Bamias","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102050_bib18","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/fon-2018-0654","article-title":"Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study","volume":"15","author":"Flannery","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmoop.2023.102050_bib19","article-title":"Utilization of systemic treatment for metastatic bladder cancer in everyday practice: results of a nation-wide population-based cohort study","volume":"25","author":"Richters","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102050_bib20","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.euf.2021.08.009","article-title":"Overall survival of patients receiving cisplatin or carboplatin for primary metastatic urothelial carcinoma of the bladder: a contemporary Dutch nationwide cohort study","volume":"8","author":"Richters","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102050_bib21","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.euf.2022.02.007","article-title":"Reassessment of the efficacy of carboplatin for metastatic urothelial carcinoma in the era of immunotherapy: a systematic review and meta-analysis","volume":"8","author":"Mori","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102050_bib22","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1016\/j.clgc.2021.12.017","article-title":"Evidence or prejudice? Critical re-analysis of randomized controlled trials comparing overall survival after cisplatin versus carboplatin-based regimens in advanced urothelial carcinoma","volume":"20","author":"Richters","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2023.102050_bib23","doi-asserted-by":"crossref","first-page":"S483","DOI":"10.1016\/j.jval.2020.08.477","article-title":"Treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial cancer in England: results of a longitudinal observational cohort study","volume":"23","author":"Kearney","year":"2020","journal-title":"Value Health"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2023.102050_bib24","doi-asserted-by":"crossref","first-page":"S480","DOI":"10.1016\/j.jval.2020.08.466","article-title":"Utilising Public Health England datasets to establish a standing cohort of patients with metastatic bladder cancer: initial results and algorithm defining disease progression","volume":"23","author":"Davies","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.esmoop.2023.102050_bib25","article-title":"Utilization of systemic therapy for treatment of advanced urothelial carcinoma: lessons from real world experience","volume":"27","author":"Swami","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.esmoop.2023.102050_bib26","doi-asserted-by":"crossref","first-page":"S1338","DOI":"10.1016\/j.annonc.2022.07.1828","article-title":"Factors associated with the receipt of systemic treatment (tx) for metastatic urothelial carcinoma (mUC) in England","volume":"33","author":"Knott","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2023.102050_bib27","doi-asserted-by":"crossref","first-page":"S713","DOI":"10.1016\/j.annonc.2021.08.097","article-title":"Real-world (RW) treatment (tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) tx: results from IMPACT UC","volume":"32","author":"Bilen","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2023.102050_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.11.014","article-title":"Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States","volume":"40","author":"Geynisman","year":"2022","journal-title":"Urol Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2023.102050_bib29","article-title":"Defining \u201cplatinum-ineligible\u201d patients with metastatic urothelial cancer (mUC)","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2023.102050_bib30","volume":"40","author":"Milloy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102050_bib31","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10236","key":"10.1016\/j.esmoop.2023.102050_bib32","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102050_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102050_bib34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","article-title":"Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial","volume":"52","author":"Dogliotti","year":"2007","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102050_bib35","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102050_bib36","article-title":"Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis","volume":"8","author":"Apolo","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"19","key":"10.1016\/j.esmoop.2023.102050_bib37","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-19-4162","article-title":"Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275","volume":"26","author":"Galsky","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10122","key":"10.1016\/j.esmoop.2023.102050_bib38","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2023.102050_bib39","first-page":"1337","article-title":"A\u00a0real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients in Germany","volume":"9","author":"Niegisch","year":"2018","journal-title":"J\u00a0Cancer"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2023.102050_bib40","doi-asserted-by":"crossref","first-page":"S716","DOI":"10.1016\/j.annonc.2021.08.103","article-title":"Treatment pattern and overall survival among patients with locally advanced or metastatic urothelial carcinoma: results from a complete nationwide unselected real-world registry study in Denmark from 2010 to 2017","volume":"32","author":"Jensen","year":"2021","journal-title":"Ann Oncol"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2023.102050_bib41","article-title":"Disease management and frontline treatment of locally advanced or metastatic urothelial (la\/mUC) carcinoma: the U.S. physician PARADIGM study","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.102050_bib42","doi-asserted-by":"crossref","first-page":"S714","DOI":"10.1016\/j.annonc.2021.08.100","article-title":"Treatment patterns among patients with advanced urothelial carcinoma (aUC) in the USA","volume":"32","author":"Morgans","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.102050_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2020.12.002","article-title":"Real-world treatment patterns and overall survival in locally advanced and metastatic urothelial tract cancer patients treated with chemotherapy in Denmark in the preimmunotherapy era: a nationwide, population-based study","volume":"24","author":"Omland","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.esmoop.2023.102050_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102187","article-title":"Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: applying clinical trial findings to clinical practice","volume":"97","author":"Grivas","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.esmoop.2023.102050_bib45","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10064","key":"10.1016\/j.esmoop.2023.102050_bib46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2023.102050_bib47","series-title":"Tecentriq (atezolizumab). Summary of Product Characteristics","year":"2023"},{"key":"10.1016\/j.esmoop.2023.102050_bib48","series-title":"Keytruda (pembrolizumab). Summary of Product Characteristics","year":"2022"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2023.102050_bib49","article-title":"Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the phase 3 IMvigor130 study","volume":"41","author":"Bamias","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.102050_bib50","series-title":"Tecentriq (atezolizumab). Prescribing Information","year":"2022"},{"key":"10.1016\/j.esmoop.2023.102050_bib51","series-title":"Keytruda (pembrolizumab). Prescribing Information","year":"2023"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2023.102050_bib52","article-title":"Atezolizumab (atezo) + platinum\/gemcitabine (plt\/gem) vs placebo + plt\/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): final OS from the randomized phase 3 IMvigor130 study","volume":"41","author":"Galsky","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.102050_bib53","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102050_bib54","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2023.102050_bib56","article-title":"First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): a phase 3, randomized, double-blind study","volume":"40","author":"Loriot","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2023.102050_bib57","doi-asserted-by":"crossref","first-page":"S1441","DOI":"10.1016\/j.annonc.2022.08.079","article-title":"Study EV-103 cohort K: antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la\/mUC)","volume":"33","author":"Rosenberg","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102050_bib58","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.102050_bib59","series-title":"Padcev (enfortumab vedotin-ejfv). Prescribing Information","year":"2023"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2023.102050_bib60","article-title":"302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2023.102050_bib61","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9699","key":"10.1016\/j.esmoop.2023.102050_bib62","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.esmoop.2023.102050_bib63","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2023.102050_bib64","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10106","key":"10.1016\/j.esmoop.2023.102050_bib65","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.esmoop.2023.102050_bib66","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11523-019-00665-1","article-title":"Immune checkpoint inhibitors as switch or continuation maintenance therapy in solid tumors: rationale and current state","volume":"14","author":"Grivas","year":"2019","journal-title":"Target Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102050_bib67","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/cpt.986","article-title":"Population modeling of tumor kinetics and overall survival to identify prognostic and predictive biomarkers of efficacy for durvalumab in patients with urothelial carcinoma","volume":"103","author":"Zheng","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"19","key":"10.1016\/j.esmoop.2023.102050_bib68","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.2217\/fon-2021-1631","article-title":"Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer","volume":"18","author":"Powles","year":"2022","journal-title":"Future Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2023.102050_bib69","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2023.102050_bib70","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy","volume":"41","author":"Sridhar","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2023.102050_bib71","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.19.03091","article-title":"Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer","volume":"38","author":"Galsky","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2023.102050_bib72","article-title":"Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial","volume":"41","author":"Bellmunt","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2023.102050_bib73","article-title":"Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2023.102050_bib74","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial","volume":"39","author":"Powles","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2023.102050_bib75","article-title":"Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy","volume":"39","author":"Loriot","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2023.102050_bib76","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance","volume":"39","author":"Sridhar","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102050_bib77","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2023.03.030","article-title":"Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 phase 3 trial","volume":"84","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2023.102050_bib78","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy","volume":"40","author":"P\u00e9rez-Valderrama","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102050_bib79","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/s41591-021-01579-0","article-title":"Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2023.102050_bib80","doi-asserted-by":"crossref","first-page":"S1442","DOI":"10.1016\/j.annonc.2022.08.080","article-title":"Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102050_bib81","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","article-title":"Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma","volume":"83","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2023.102050_bib82","article-title":"Full analysis from AVENANCE: a real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC)","volume":"41","author":"Barthelemy","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2023.102050_bib83","article-title":"READY: real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la\/mUC)","volume":"41","author":"Antonuzzo","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2023.102050_bib88","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.clgc.2023.06.008","article-title":"Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients with advanced urothelial carcinoma (aUC): \"real world\" experience","volume":"21","author":"Bakaloudi","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.esmoop.2023.102050_bib84","unstructured":"Park SH, Rah SY, Seo HK, et\u00a0al. First results of a Korean expanded access program of avelumab first-line maintenance in patients with locally advanced or metastatic urothelial carcinoma. Poster presented at: 15th Annual Meeting of the Korean Society of Medical Oncology & 2022 International Congress. September 1-2, 2022; Seoul, Korea."},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2023.102050_bib85","article-title":"Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced\/metastatic urothelial carcinoma (la\/mUC) (PATRIOT-II)","volume":"41","author":"Grivas","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2023.102050_bib86","first-page":"266","article-title":"Avenue: a prospective observational study of real-world treatment patterns and treatment outcomes in patients with advanced or metastatic urothelial carcinoma treated with avelumab first-line maintenance therapy","volume":"44","author":"Gschwend","year":"2021","journal-title":"Oncol Res Treat"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2023.102050_bib87","article-title":"SPADE: design of a real-world observational study of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (UC) in the Asia-Pacific (APAC) region","volume":"41","author":"Su","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102050_bib89","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jjco\/hyac186","article-title":"Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study","volume":"53","author":"Miyake","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.102050_bib90","series-title":"Bavencio (avelumab). Summary of Product Characteristics","year":"2023"},{"key":"10.1016\/j.esmoop.2023.102050_bib91","series-title":"Bavencio (avelumab). Prescribing Information","year":"2023"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2023.102050_bib92","doi-asserted-by":"crossref","first-page":"S1343","DOI":"10.1016\/j.annonc.2022.07.1838","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): results from patients with \u226512 mo of treatment in JAVELIN Bladder 100","volume":"33","author":"Aragon-Ching","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.102050_bib94","series-title":"Padcev (enfortumab vedotin). Summary of Product Characteristics","year":"2023"},{"key":"10.1016\/j.esmoop.2023.102050_bib95","series-title":"Balversa (erdafitinib). Prescribing Information","year":"2023"},{"key":"10.1016\/j.esmoop.2023.102050_bib96","series-title":"Javlor (vinflunine). Summary of Product Characteristics","year":"2022"},{"key":"10.1016\/j.esmoop.2023.102050_bib97","series-title":"Trodelvy (sacituzumab govitecan). Prescribing Information","year":"2023"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2023.102050_bib98","article-title":"Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: exploratory analyses from JAVELIN Bladder 100","volume":"40","author":"Bellmunt","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2023.102050_bib99","article-title":"Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): analysis of time to end of next-line therapy in\u00a0JAVELIN Bladder 100","volume":"39","author":"Grivas","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2023.102050_bib102","article-title":"MAIN-CAV: phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001)","volume":"40","author":"Gupta","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2023.102050_bib103","first-page":"A695","article-title":"JAVELIN Bladder Medley: a phase 2 trial of avelumab in combination with other antitumor drugs as first-line maintenance therapy for advanced urothelial carcinoma","volume":"10","author":"Hoffman-Censits","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2023.102050_bib104","article-title":"TROPHY-U-01 cohort 5: evaluation of maintenance sacituzumab govitecan (SG) plus zimberelimab (ZIM), ZIM, or avelumab in cisplatin-eligible patients (pts) with unresectable or metastatic urothelial cancer (mUC)","volume":"41","author":"Powles","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2023.102050_bib105","article-title":"TROPHY-U-01 cohort 6: sacituzumab govitecan (SG), SG plus zimberelimab (ZIM), SG plus ZIM plus domvanalimab (DOM), or carboplatin (CARBO)\u00a0+ gemcitabine (GEM) in cisplatin-ineligible patients (pts) with treatment-naive metastatic urothelial cancer (mUC)","volume":"41","author":"Duran","year":"2023","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923012917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923012917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:32:56Z","timestamp":1761856376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923012917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2059702923012917"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.102050","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.102050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102050"}}